GlassScriptPhysician profile
Hannah V Tranchina
NPI 1851696298
$1,116.31
in general payments reported to CMS, 2019-2025
22 companies · $208 in 2025
The $208 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $191 · 2022: $215 · 2023: $307 · 2024: $195 · 2025: $208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $710.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $710.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $164.19 | 2022-2025 | Ingrezza, Ongentys |
| Pfizer INC. | $87.60 | 2022-2024 | |
| Ucb, INC. | $86.70 | 2023-2024 | Briviact |
| Astrazeneca Pharmaceuticals LP | $82.02 | 2021-2024 | Andexxa |
| Abbvie INC. | $70.12 | 2021-2025 | |
| Lundbeck LLC | $69.73 | 2021-2023 | Rexulti |
| Depuy Synthes Sales INC. | $67.69 | 2022-2023 | T-Plif, X-Pac |
| Biogen, INC. | $65.14 | 2021-2025 | Leqembi |
| Contego Medical, INC | $51.81 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $51.07 | 2023-2024 | Austedo, Ajovy, Austedo Xr |
| Genentech USA, INC. | $47.26 | 2024-2025 | Ocrevus Zunovo |
| Eisai INC. | $41.78 | 2025 | |
| Argenx US, INC. | $40.58 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Lilly USA, LLC | $33.73 | 2021-2022 | |
| Si-Bone, INC. | $25.88 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $25.46 | 2023 | Uplizna |
| Collegium Pharmaceutical, INC. | $21.04 | 2023 | Belbuca |
| Acorda Therapeutics, INC | $21.02 | 2023 | Inbrija |
| Medtronic, INC. | $16.69 | 2021 | |
| Upsher-Smith Laboratories LLC | $16.59 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $15.52 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $14.69 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Tranchina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.